Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19738337 | 0.89 | SYK (0.39) | SYKL3MBTL1MAPTTDP1ATR | |
| SCHEMBL22939319 | 0.86 | SYK (0.39) | SYKL3MBTL1MAPTTDP1ATR | |
| SCHEMBL29593210 | 0.86 | SYK (0.39) | SYKL3MBTL1MAPTTDP1ATR | |
| SCHEMBL19738339 | 0.85 | SYK (0.39) | SYKL3MBTL1MAPTTDP1ATR | |
| SCHEMBL29124868 | 0.84 | SYK (0.38) | SYKL3MBTL1MAPTTDP1ATR | |
| SCHEMBL19738338 | 0.83 | SYK (0.37) | SYKL3MBTL1MAPTTDP1ATR | |
| SCHEMBL29124870 | 0.83 | SYK (0.37) | SYKL3MBTL1MAPTTDP1ATR | |
| SCHEMBL24653331 | 0.81 | AURKA (0.40) | SYKL3MBTL1ATRAURKARPS6KB1 | |
| SCHEMBL29124862 | 0.80 | SYK (0.36) | SYKL3MBTL1MAPTTDP1AURKA | |
| SCHEMBL16146678 | 0.80 | GDA (0.39) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | VASADE BIOSCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362235-A1 | ADENYLYL CYCLASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | ADCY1, ADCY2, ADCY5 | SYK 1323/4885L3MBTL1 2316/4885MAPT 4871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.